A Phase 2 interventional study of Tislelizumab and Ociperlimab in Cervical Cancer, sponsored by BeiGene. Completed at 68 sites in 8 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-27.
Sponsored by BeiGene · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 455 studies in Uterine Cervical Neoplasms with a site in China — 205 open to participants now, 240 under way, 35 of them phase 3. Uterine Cervical Neoplasms · China.
Among the 455 studies in Uterine Cervical Neoplasms with a site in China, this one is the 121st largest by enrollment of the 360 interventional ones that give a count, is one of 52 that started in 2021, is one of 137 in phase 2, and was the 154th registered.
2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.
Browse Uterine Cervical Neoplasms studies →205 of the 455 studies in Uterine Cervical Neoplasms with a site in China are open now. Recruiting first, the newest first:
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 17–75 · Women only
Catherin Zhang · Sites in China
Ages 18–75 · Women only
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–80 · Women only
Manni Huang · Sites in China
Ages 18–75 · Women only
Sun Yat-sen University · Sites in China
Ages 18–70 · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
455 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 78 · Phase 2 174 · Phase 3 67 · Phase 4 6
First in 2005; this study’s year is marked. 52 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 178 is above the median of 100 across 1,739 interventional studies indexed under Uterine Cervical Neoplasms.
Median enrollment 90 across the 360 interventional studies, 460 across the 95 observational. Of the 87 that completed or were terminated, 12 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
121 of 455 have an industry lead sponsor. The 10 most frequent:
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
BeOne Medicines has 1 study filed under Uterine Cervical Neoplasms — fewer than ten, so there is no comparison to draw.
53 of the studies in Uterine Cervical Neoplasms with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06459687Phase 3Lee's Pharmaceutical LimitedPhase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer | 2027-09-01 |
| NCT04422366Phase 3Shanghai Bovax Biotechnology Co., Ltd.Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | 2027-09-15 |
| NCT06079671Phase 3AstraZenecaStudy of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) | 2027-11-26 |
| NCT06416696Cancer Institute and Hospital, Chinese Academy of Medical SciencesToripalimab for High-risk Locally Advanced Cervical Cancer | 2026-12 |
| NCT07860203Catherin ZhangStellate Ganglion Block and Dexmedetomidine for Postoperative Sleep in Women Undergoing Laparoscopic Gynecologic Surgery | 2026-12 |
Add all 53 to your calendar (.ics) → With an account.
Among the 455 studies in Uterine Cervical Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study tested how well and how safely the drug tislelizumab, given either alone or with another drug called ociperlimab (BGB-A1217), worked in people with cervical cancer that had come back or spread after previous treatments. The study included two groups and took place at multiple medical centers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tislelizumab 200 milligrams (mg) intravenously (IV) once every 3 weeks (Q3W) combined with ociperlimab (BGB-A1217) 900 mg IV Q3W
Biological: Tislelizumab · Biological: Ociperlimab
Tislelizumab 200 mg IV Q3W monotherapy
Biological: Tislelizumab
200 mg administered intravenously once every 3 weeks on day 1 of each cycle
Also known as: BGB-A317, TEVIMBRA®
900 mg administered intravenously once every 3 weeks on day 1 of each cycle
Also known as: BGB-A1217
Cohort 1: Objective Response Rate (ORR) Assessed by an Independent Review Committee (IRC) in PD-L1-Positive Participants
ORR is defined as the percentage of participants who had confirmed complete response (CR) or partial response (PR) as assessed by the IRC per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1). PD-L1-positive refers to participants whose tumors had a PD-L1 TAP score ≥ 5%.
Time frame: Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1.
Cohort 1: ORR Assessed by the IRC in All Treated Participants
ORR is defined as the percentage of participants who had a confirmed CR or PR as assessed by the IRC per RECIST v1.1.
Time frame: Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1.
Cohort 2: Objective Response Rate (ORR) Assessed by an Independent Review Committee in All Treated Participants
ORR is defined as the percentage of participants who had confirmed complete response (CR) or partial response (PR) as assessed by the IRC per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1).
Time frame: Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 10.40 months for Cohort 2.
ORR Assessed by the Investigator in PD-L1-Positive Participants
ORR is defined as the percentage of participants who had confirmed CR or PR as assessed by the investigator per RECIST v1.1 in the PD-L1 Score \>= 5% Safety Analysis Set.
Time frame: Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1 and 10.40 months for Cohort 2.
ORR as Assessed by the Investigator in All Treated Participants
ORR is defined as the percentage of participants who had a confirmed CR or PR as assessed by the investigator per RECIST v1.1.
Time frame: Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1 and 10.40 months for Cohort 2.
Duration of Response (DOR) Assessed by the IRC
DOR is defined as the time from the first confirmed objective response until the first documentation of progression or death, whichever occurred first, assessed by the IRC according to RECIST v1.1 in the Safety Analysis Set.
Time frame: Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1 and 10.40 months for Cohort 2.
Duration of Response (DOR) Assessed by the Investigator
DOR is defined as the time from the first confirmed objective response until the first documentation of progression or death, whichever comes first, assessed by the investigator according to RECIST v1.1 in the Safety Analysis Set. Data was based on number of responders.
Time frame: Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1 and 10.40 months for Cohort 2.
Progression Free Survival (PFS)
Defined as the time from the date of first dose of study drug to the date of first documentation of disease progression or death, whichever occurred first as assessed by both the IRC and the investigator's review per RECIST v1.1 in the Safety Analysis Set.
Time frame: Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1 and 10.40 months for Cohort 2.
Time to Response (TTR) Assessed by the IRC
TTR is defined as the time from the date of first dose of study drug to the first documentation of response as assessed by the IRC per RECIST v1.1, in the Safety Analysis Set.
Time frame: Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up was 7.36 months for Cohort 1 and 10.40 months for Cohort 2.
Time to Response (TTR) Assessed by the Investigator
TTR is defined as the time from the date of first dose of study drug to the first documentation of response as assessed by the investigator per RECIST v1.1, in the Safety Analysis Set.
Time frame: Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up was 7.36 months for Cohort 1 and 10.40 months for Cohort 2.
Disease Control Rate (DCR)
DCR is defined as the percentage of participants who achieve CR, PR, or stable disease (SD) as assessed by both the IRC and investigator per RECIST v1.1 in the Safety Analysis Set.
Time frame: Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1 and 10.40 months for Cohort 2.
Clinical Benefit Rate (CBR)
Defined as the percentage of participants who achieve CR, PR, or durable SD (SD ≥ 24 weeks) as assessed by both the IRC and investigator per RECIST v1.1 in the Safety Analysis Set.
Time frame: Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1 and 10.40 months for Cohort 2.
Overall Survival (OS)
Overall survival is defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using Kaplan-Meier methodology.
Time frame: Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1 and 10.40 months for Cohort 2.
Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status/Quality of Life, Physical Functioning, and Pain Scores
The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life. Lower scores in symptom scales indicate better quality of life.
Time frame: Baseline to Cycles 3 and 5 ( Each cycle was 21 days)
Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Symptom Specific Scale for Cervical Cancer (EORTC QLQ-CX24) Index Score
QLQ-CX24 is the cervical cancer module of the QLQ-C30. CX24 is comprised of 24 questions grouped into 3 symptom scales and 6 single symptom items. Each question is answered on a scale from 1 (not at all) to 4 (very much). The scales include Symptom Experience (11 items), Body Image (3 items) and Sexual/vaginal Functioning (4 items). The single symptom items include Lymphedema, Peripheral Neuropathy, Menopausal Symptoms, Sexual Worry, Sexual Activity and Sexual Enjoyment. Raw scores are transformed into a 0 to 100 scale via linear transformation. The Index score is calculated as the average of the 3 symptom scales and 6 single item scores. Lower scores indicate better HRQoL.
Time frame: Baseline to Cycles 3 and 5 ( Each cycle was 21 days)
Number of Participants Experiencing Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drugs, whether considered related to study drugs or not. An SAE is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Was a congenital anomaly/birth defect * Was considered a significant medical AE by the investigator based on medical judgement (eg, may jeopardize the patient or may require medical/surgical intervention to prevent one of the outcomes listed above).
Time frame: From the first dose of study drug to 30 days after the last dose; maximum treatment exposure was 23.5 months.
Serum Ociperlimab (BGB-A1217) Concentrations at Specified Timepoints
The timepoints are defined as predose (within 60 minutes before starting infusion) and postdose (within 30 minutes after the end of infusion).
Time frame: Day 1 of Cycles 1, 2, 5, 9, and 17 (each cycle was 21 days)
Serum Tislelizumab Concentrations at Specified Timepoints
The timepoints are defined as predose (within 60 minutes before starting infusion) and postdose (within 30 minutes after the end of infusion).
Time frame: Day 1 of Cycles 1, 2, 5, 9, and 17 (each cycle is 21 days)
Number of Participants Who Developed Positive Anti-drug Antibodies (ADAs) to Ociperlimab
Number and percentage of participants who developed detectable ADAs to ociperlimab during the treatment period.
Time frame: Samples for ADA analysis were collected predose on Day 1 of Cycles 1, 2, 5, 9 and 17, and at the Safety Follow-up Visit (30 days after last dose) up to the immunogenicity data cut-off date of June 1, 2023 (approximately 21 months).
Number of Participants Who Developed Anti-drug Antibodies (ADAs) to Tislelizumab
Number and percentage of participants who developed detectable ADAs during the treatment period.
Time frame: Samples for ADA analysis were collected predose on Day 1 of Cycles 1, 2, 5, 9 and 17, and at the Safety Follow-up Visit (30 days after last dose), up to the immunogenicity data cut-off date of June 1, 2023 (approximately 21 months).
Participants were enrolled in multiple study centers in China, South Korea, and Europe.The first participant dosed was on March 3rd, 2021 and the last participant completed on August 31st, 2023.
| Milestone | Cohort 1: Ociperlimab + Tislelizumab | Cohort 2: Tislelizumab |
|---|---|---|
| Started | 138 | 40 |
| Completed | 0 | 0 |
| Not completed | 138 | 40 |
| Withdrew: Death | 79 | 19 |
| Withdrew: Sponsor ended study | 47 | 18 |
| Withdrew: Withdrawal by subject | 10 | 2 |
| Withdrew: Lost to follow-up | 2 | 1 |
ORR is defined as the percentage of participants who had confirmed complete response (CR) or partial response (PR) as assessed by the IRC per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1). PD-L1-positive refers to participants whose tumors had a PD-L1 TAP score ≥ 5%.
| percentage of participants | Cohort 1: Ociperlimab + Tislelizumab |
|---|---|
| Cohort 1: Objective Response Rate (ORR) Assessed by an Independent Review Committee (IRC) in PD-L1-Positive Participants | 26.2 (17.2 to 36.9) |
ORR is defined as the percentage of participants who had a confirmed CR or PR as assessed by the IRC per RECIST v1.1.
| percentage of participants | Cohort 1: Ociperlimab + Tislelizumab |
|---|---|
| Cohort 1: ORR Assessed by the IRC in All Treated Participants | 22.5 (15.8 to 30.3) |
ORR is defined as the percentage of participants who had confirmed complete response (CR) or partial response (PR) as assessed by the IRC per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1).
| percentage of participants | Cohort 2: Tislelizumab |
|---|---|
| Cohort 2: Objective Response Rate (ORR) Assessed by an Independent Review Committee in All Treated Participants | 32.5 (18.6 to 49.1) |
ORR is defined as the percentage of participants who had confirmed CR or PR as assessed by the investigator per RECIST v1.1 in the PD-L1 Score \>= 5% Safety Analysis Set.
| percentage of participants | Cohort 1: Ociperlimab + Tislelizumab | Cohort 2: Tislelizumab |
|---|---|---|
| ORR Assessed by the Investigator in PD-L1-Positive Participants | 25.0 (16.2 to 35.6) | 30 (11.9 to 54.3) |
ORR is defined as the percentage of participants who had a confirmed CR or PR as assessed by the investigator per RECIST v1.1.
| percentage of participants | Cohort 1: Ociperlimab + Tislelizumab | Cohort 2: Tislelizumab |
|---|---|---|
| ORR as Assessed by the Investigator in All Treated Participants | 21.0 (14.5 to 28.8) | 22.5 (10.8 to 38.5) |
DOR is defined as the time from the first confirmed objective response until the first documentation of progression or death, whichever occurred first, assessed by the IRC according to RECIST v1.1 in the Safety Analysis Set.
| Months | Cohort 1: Ociperlimab + Tislelizumab | Cohort 2: Tislelizumab |
|---|---|---|
| Duration of Response (DOR) Assessed by the IRC | NA (5.6 to NA) | NA (4.1 to NA) |
DOR is defined as the time from the first confirmed objective response until the first documentation of progression or death, whichever comes first, assessed by the investigator according to RECIST v1.1 in the Safety Analysis Set. Data was based on number of responders.
| Months | Cohort 1: Ociperlimab + Tislelizumab | Cohort 2: Tislelizumab |
|---|---|---|
| Duration of Response (DOR) Assessed by the Investigator | NA (5.5 to NA) | NA (5.6 to NA) |
Defined as the time from the date of first dose of study drug to the date of first documentation of disease progression or death, whichever occurred first as assessed by both the IRC and the investigator's review per RECIST v1.1 in the Safety Analysis Set.
| Months | Cohort 1: Ociperlimab + Tislelizumab | Cohort 2: Tislelizumab |
|---|---|---|
| IRC | 3.5 (2.6 to 4.9) | 5.7 (2.3 to 8.1) |
| Investigator | 3.9 (2.6 to 4.4) | 5.7 (2.6 to 9.2) |
TTR is defined as the time from the date of first dose of study drug to the first documentation of response as assessed by the IRC per RECIST v1.1, in the Safety Analysis Set.
| Weeks | Cohort 1: Ociperlimab + Tislelizumab | Cohort 2: Tislelizumab |
|---|---|---|
| Time to Response (TTR) Assessed by the IRC | 9.02 ± 4.704 | 11.78 ± 4.709 |
TTR is defined as the time from the date of first dose of study drug to the first documentation of response as assessed by the investigator per RECIST v1.1, in the Safety Analysis Set.
| Weeks | Cohort 1: Ociperlimab + Tislelizumab | Cohort 2: Tislelizumab |
|---|---|---|
| Time to Response (TTR) Assessed by the Investigator | 10.66 ± 3.010 | 8.92 ± 3.174 |
DCR is defined as the percentage of participants who achieve CR, PR, or stable disease (SD) as assessed by both the IRC and investigator per RECIST v1.1 in the Safety Analysis Set.
| percentage of participants | Cohort 1: Ociperlimab + Tislelizumab | Cohort 2: Tislelizumab |
|---|---|---|
| IRC | 63.0 (54.4 to 71.1) | 67.5 (50.9 to 81.4) |
| Investigator | 62.3 (53.7 to 70.4) | 75.0 (58.8 to 87.3) |
Defined as the percentage of participants who achieve CR, PR, or durable SD (SD ≥ 24 weeks) as assessed by both the IRC and investigator per RECIST v1.1 in the Safety Analysis Set.
| percentage of participants | Cohort 1: Ociperlimab + Tislelizumab | Cohort 2: Tislelizumab |
|---|---|---|
| IRC | 29.0 (21.6 to 37.3) | 50.0 (33.8 to 66.2) |
| Investigator | 31.2 (23.6 to 39.6) | 50.0 (33.8 to 66.2) |
Overall survival is defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using Kaplan-Meier methodology.
| Months | Cohort 1: Ociperlimab + Tislelizumab | Cohort 2: Tislelizumab |
|---|---|---|
| Overall Survival (OS) | 9.0 (8.1 to 10.4) | NA (10.5 to NA) |
The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life. Lower scores in symptom scales indicate better quality of life.
| Score on a scale | Cohort 1: Ociperlimab + Tislelizumab | Cohort 2: Tislelizumab |
|---|---|---|
| GHS/QoL: Baseline Score | 64.21 ± 20.821 | 62.06 ± 22.402 |
| GHS/QoL: Change from Baseline to Cycle 3 Day 1 | 0.37 ± 22.158 | 5.30 ± 23.088 |
| GHS/QoL: Change from Baseline to Cycle 5 Day 1 | 3.46 ± 18.355 | 5.13 ± 21.995 |
| Physical Functioning: Baseline Score | 78.91 ± 19.211 | 76.67 ± 22.501 |
| Physical Functioning: Change from Baseline at Cycle 3 Day 1 | -2.62 ± 16.582 | 1.82 ± 18.876 |
| Physical Functioning: Change from Baseline at Cycle 5 Day 1 | 0.00 ± 14.927 | 5.38 ± 16.113 |
| Pain: Baseline Score | 27.73 ± 28.070 | 30.26 ± 27.084 |
| Pain: Change from Baseline at Cycle 3 Day 1 | -2.08 ± 21.820 | -9.09 ± 26.051 |
| Pain: Change from Baseline at Cycle 5 Day 1 | -2.16 ± 22.353 | -8.97 ± 24.599 |
QLQ-CX24 is the cervical cancer module of the QLQ-C30. CX24 is comprised of 24 questions grouped into 3 symptom scales and 6 single symptom items. Each question is answered on a scale from 1 (not at all) to 4 (very much). The scales include Symptom Experience (11 items), Body Image (3 items) and Sexual/vaginal Functioning (4 items). The single symptom items include Lymphedema, Peripheral Neuropathy, Menopausal Symptoms, Sexual Worry, Sexual Activity and Sexual Enjoyment. Raw scores are transformed into a 0 to 100 scale via linear transformation. The Index score is calculated as the average of the 3 symptom scales and 6 single item scores. Lower scores indicate better HRQoL.
| score on a scale | Cohort 1: Ociperlimab + Tislelizumab | Cohort 2: Tislelizumab |
|---|---|---|
| Baseline Score | 30.86 ± 6.942 | 31.43 ± 4.497 |
| Change from Baseline at Cycle 3 Day 1 | 0.61 ± 5.915 | -0.71 ± 4.163 |
| Change from Baseline at Cycle 5 Day 1 | -0.15 ± 5.790 | 1.05 ± 4.227 |
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drugs, whether considered related to study drugs or not. An SAE is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Was a congenital anomaly/birth defect * Was considered a significant medical AE by the investigator based on medical judgement (eg, may jeopardize the patient or may require medical/surgical intervention to prevent one of the outcomes listed above).
| Participants | Cohort 1: Ociperlimab + Tislelizumab | Cohort 2: Tislelizumab |
|---|---|---|
| Number of Participants with at least one TEAE | 135 | 39 |
| Number of participants with at least one SAE | 61 | 17 |
The timepoints are defined as predose (within 60 minutes before starting infusion) and postdose (within 30 minutes after the end of infusion).
| μg/mL | Cohort 1 (Predose) | Cohort 1 (Postdose) |
|---|---|---|
| Cycle 1 Day 1 | 0.00 ± NA | 363.19 ± 24.21 |
| Cycle 2 Day 1 | 46.60 ± 46.98 | — |
| Cycle 5 Day 1 | 82.57 ± 55.30 | 440.70 ± 25.35 |
| Cycle 9 Day 1 | 89.13 ± 56.58 | — |
| Cycle 17 Day 1 | 88.84 ± 63.62 | — |
The timepoints are defined as predose (within 60 minutes before starting infusion) and postdose (within 30 minutes after the end of infusion).
| μg/mL | Cohort 1 (Predose) | Cohort 1 (Postdose) | Cohort 2 (Predose) | Cohort 2 (Postdose) |
|---|---|---|---|---|
| Cycle 1 Day 1 | 0.00 ± NA | 77.38 ± 21.78 | 0.00 ± NA | 84.24 ± 18.19 |
| Cycle 2 Day 1 | 17.86 ± 35.69 | — | 20.03 ± 36.62 | — |
| Cycle 5 Day 1 | 36.66 ± 44.97 | 113.80 ± 24.68 | 41.51 ± 42.89 | 128.48 ± 24.06 |
| Cycle 9 Day 1 | 42.84 ± 46.50 | — | 56.78 ± 28.55 | — |
| Cycle 17 Day 1 | 45.16 ± 55.71 | — | 56.25 ± 21.56 | — |
Number and percentage of participants who developed detectable ADAs to ociperlimab during the treatment period.
| Participants | Cohort 1: Ociperlimab + Tislelizumab |
|---|---|
| Number of Participants Who Developed Positive Anti-drug Antibodies (ADAs) to Ociperlimab | 0 |
Number and percentage of participants who developed detectable ADAs during the treatment period.
| Participants | Cohort 1: Ociperlimab + Tislelizumab | Cohort 2: Tislelizumab |
|---|---|---|
| Number of Participants Who Developed Anti-drug Antibodies (ADAs) to Tislelizumab | 19 | 7 |
Collected over All-cause mortality: From randomization through the end of study; up to 24.5 months. Adverse events: From the first dose to 30 days after the last dose; maximum treatment exposure was 23.5 months.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Ociperlimab + Tislelizumab | 79/138 (57.2%) | 61/138 (44.2%) | 128/138 (92.8%) |
| Cohort 2: Tislelizumab | 19/40 (47.5%) | 17/40 (42.5%) | 37/40 (92.5%) |
| Event | Cohort 1: Ociperlimab + Tislelizumab | Cohort 2: Tislelizumab |
|---|---|---|
| Urinary tract infectionInfections and infestations | 11/138 | 2/40 |
| COVID-19Infections and infestations | 1/138 | 3/40 |
| HydronephrosisRenal and urinary disorders | 4/138 | 3/40 |
| IleusGastrointestinal disorders | 3/138 | 2/40 |
| PyrexiaGeneral disorders | 5/138 | 2/40 |
| AnaemiaBlood and lymphatic system disorders | 4/138 | 0/40 |
| Multiple organ dysfunction syndromeGeneral disorders | 4/138 | 0/40 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 4/138 | 0/40 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/138 | 1/40 |
| Large intestinal obstructionGastrointestinal disorders | 0/138 | 1/40 |
| Event | Cohort 1: Ociperlimab + Tislelizumab | Cohort 2: Tislelizumab |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 48/138 | 15/40 |
| Urinary tract infectionInfections and infestations | 16/138 | 10/40 |
| HypothyroidismEndocrine disorders | 27/138 | 8/40 |
| Decreased appetiteMetabolism and nutrition disorders | 15/138 | 8/40 |
| HypokalaemiaMetabolism and nutrition disorders | 20/138 | 8/40 |
| NauseaGastrointestinal disorders | 27/138 | 6/40 |
| PyrexiaGeneral disorders | 27/138 | 7/40 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 25/138 | 4/40 |
| Aspartate aminotransferase increasedInvestigations | 24/138 | 5/40 |
| Abdominal painGastrointestinal disorders | 9/138 | 6/40 |
The Safety Analysis Set is defined as all participants who received \>= 1 dose of any study drug for each cohort.
| Age, Continuous(years) | Cohort 1: Ociperlimab + Tislelizumab | Cohort 2: Tislelizumab | Total |
|---|---|---|---|
| Mean | 52.7 ± 10.28 | 51.2 ± 9.74 | 52.3 ± 10.15 |
| Sex/Gender, Customized(Participants) | Cohort 1: Ociperlimab + Tislelizumab | Cohort 2: Tislelizumab | Total |
|---|---|---|---|
| Female | 138 | 40 | 178 |
| Race/Ethnicity, Customized(Participants) | Cohort 1: Ociperlimab + Tislelizumab | Cohort 2: Tislelizumab | Total |
|---|---|---|---|
| Asian | 117 | 37 | 154 |
| White | 21 | 3 | 24 |
| Region of Enrollment(participants) | Cohort 1: Ociperlimab + Tislelizumab | Cohort 2: Tislelizumab | Total |
|---|---|---|---|
| China | 71 | 17 | 88 |
| South Korea | 30 | 8 | 38 |
| Taiwan | 10 | 6 | 16 |
| Ukraine | 10 | 0 | 10 |
| Russia | 8 | 3 | 11 |
| Thailand | 6 | 6 | 12 |
| Bulgaria | 2 | 0 | 2 |
| Poland | 1 | 0 | 1 |
| Eastern Cooperative Oncology Group Performance Status(Participants) | Cohort 1: Ociperlimab + Tislelizumab | Cohort 2: Tislelizumab | Total |
|---|---|---|---|
| 0 | 53 | 16 | 69 |
| 1 | 85 | 24 | 109 |
| Programmed Death-Ligand 1 (PD-L1) Expression(Participants) | Cohort 1: Ociperlimab + Tislelizumab | Cohort 2: Tislelizumab | Total |
|---|---|---|---|
| PD-L1 Score >= 5% | 84 | 20 | 104 |
| PD-L1 Score < 5% | 53 | 20 | 73 |
| Not Evaluable | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Feb 2021 to primary completion in Jun 2022, 16 months.
Results were first posted in Apr 2025, 2 years 10 months after primary completion.
Of 50 industry-sponsored phase 2 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 46. This study's 16 months is below that.
Counting every sponsor, half of 204 studies reached it within 42 months; a quarter within 29 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tislelizumab